Annual Report FY25-26 submitted; 41st AGM on July 15, record date July 8

BLISSGVS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+4.6%1-day move

₹469.65

prior close

₹469.95

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.9+1.4+1.0-1.0+4.6+13.1+14.9+10.8+11.9+4.3+9.0-1.6——

Up moveDown movePending

AI summary

Bliss GVS Pharma submitted its 41st Annual Report for FY25-26 to exchanges. The 41st AGM is set for July 15, 2026 via video conference. Record date for final dividend is July 8, 2026, with payment by August 14. Consolidated revenue rose to ₹9,271 Mn from ₹8,097 Mn, EBITDA at ₹1,640 Mn, PBT ₹1,921 Mn, and PAT ₹1,347 Mn. EBITDA margin was 18%, PBT margin 21%. The company runs 6 manufacturing units and sells in 60 plus countries. Borrowings fell 96% (about ₹680 Mn), strengthening the balance sheet.

Likely market impact

Confirms healthy FY25-26 with revenue growth and margin expansion. Final dividend clarity and lower debt are positive for shareholders.